Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics

Journal of Translational Medicine

David J Goldstein¹  Lalage M Wakefield³  Jin-Qiu Chen² 

[1] Office of Science and Technology Resources, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda 20892, MD, USA;Collaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 2140, Bethesda 20892, MD, USA;Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda 20892, MD, USA

关键词: Molecular diagnostic;    Proteomics;    Biomarker;    Cell signaling;    Simple western;    Capillary nano-immunoassay;   

Others  :  1233511
DOI  :  10.1186/s12967-015-0537-6

 received in 2015-02-18, accepted in 2015-05-14,  发布年份 2015

【 摘 要 】

There is an emerging demand for the use of molecular profiling to facilitate biomarker identification and development, and to stratify patients for more efficient treatment decisions with reduced adverse effects. In the past decade, great strides have been made to advance genomic, transcriptomic and proteomic approaches to address these demands. While there has been much progress with these large scale approaches, profiling at the protein level still faces challenges due to limitations in clinical sample size, poor reproducibility, unreliable quantitation, and lack of assay robustness. A novel automated capillary nano-immunoassay (CNIA) technology has been developed. This technology offers precise and accurate measurement of proteins and their post-translational modifications using either charge-based or size-based separation formats. The system not only uses ultralow nanogram levels of protein but also allows multi-analyte analysis using a parallel single-analyte format for increased sensitivity and specificity. The high sensitivity and excellent reproducibility of this technology make it particularly powerful for analysis of clinical samples. Furthermore, the system can distinguish and detect specific protein post-translational modifications that conventional Western blot and other immunoassays cannot easily capture. This review will summarize and evaluate the latest progress to optimize the CNIA system for comprehensive, quantitative protein and signaling event characterization. It will also discuss how the technology has been successfully applied in both discovery research and clinical studies, for signaling pathway dissection, proteomic biomarker assessment, targeted treatment evaluation and quantitative proteomic analysis. Lastly, a comparison of this novel system with other conventional immuno-assay platforms is performed.

【 授权许可】

   
2015 Chen et al.

【 图 表 】

Figure1.

Figure2.

Figure3.

Figure4.

Figure1.

Figure2.

Figure3.

Figure4.

【 参考文献 】

• [1]Miller I, Ashton-Chess J, Spolders H, Fert V, Ferrara J, Kroll W et al.. Market access challenges in the EU for high medical value diagnostic tests. Pers Med. 2011; 8:137-148.
• [2]Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med. 2007; 357:39-51.
• [3]Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol. 2009; 16:196-203.
• [4]Tan EH, Ramlau R, Pluzanska A, Kuo HP, Reck M, Milanowski J et al.. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol. 2010; 21:217-222.
• [5]Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC et al.. Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res. 2008; 14:8213-8220.
• [6]Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S et al.. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA. 2008; 105:19432-19437.
• [7]Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR et al.. International network of cancer genome projects. Nature. 2010; 464:993-998.
• [8]Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al.. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366:883-892.
• [9]Din S, Lennon AM, Arnott ID, Hupp T, Satsangi J. Technology insight: the application of proteomics in gastrointestinal disease. Nat Clin Pract Gastroenterol Hepatol. 2007; 4:372-385.
• [10]Haab BB. Antibody arrays in cancer research. Mol Cell Proteomics. 2005; 4:377-383.
• [11]A gene-centric human proteome project: HUPO–the human proteome organization. Mol Cell Proteomics. 2010; 9:427-429.
• [12]Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999; 19:1720-1730.
• [13]Brennan DJ, O’Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer. 2010; 10:605-617.
• [14]Kopf E, Zharhary D. Antibody arrays—an emerging tool in cancer proteomics. Int J Biochem Cell Biol. 2007; 39:1305-1317.
• [15]VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn. 2007; 7:625-633.
• [16]Hughes AJ, Lin RK, Peehl DM, Herr AE. Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci USA. 2012; 109:5972-5977.
• [17]Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF. Technology insight: pharmacoproteomics for cancer–promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. 2006; 3:256-268.
• [18]O’Neill RA, Bhamidipati A, Bi X, Deb-Basu D, Cahill L, Ferrante J et al.. Isoelectric focusing technology quantifies protein signaling in 25 cells. Proc Natl Acad Sci USA. 2006; 103:16153-16158.
• [19]Besong Agbo D, Klafki H, Poschmann G, Seyfarth K, Genius J, Janssen C et al.. Development of a capillary isoelectric focusing immunoassay to measure DJ-1 isoforms in biological samples. Anal Biochem. 2013; 443:197-204.
• [20]Chen JQ, Heldman MR, Herrmann MA, Kedei N, Woo W, Blumberg PM et al.. Absolute quantitation of endogenous proteins with precision and accuracy using a capillary Western system. Anal Biochem. 2013; 442:97-103.
• [21]Harding A. Life science technologies: not your PI’s western blot. Science. 2013; 339:1100-1102.
• [22]Fan AC, Deb-Basu D, Orban MW, Gotlib JR, Natkunam Y, O’Neill R et al.. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med. 2009; 15:566-571.
• [23]Iacovides DC, Johnson AB, Wang N, Boddapati S, Korkola J, Gray JW. Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. Mol Cell Proteomics. 2013; 12:3210-3220.
• [24]Klein BY, Tamir H, Hirschberg DL, Glickstein SB, Welch MG. Oxytocin modulates mTORC1 pathway in the gut. Biochem Biophys Res Commun. 2013; 432:466-471.
• [25]Kedei N, Telek A, Czap A, Lubart ES, Czifra G, Yang D et al.. The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line. Biochem Pharmacol. 2011; 81:1296-1308.
• [26]Klamer SE, Kuijk CGM, Hordijk PL, van der Schoot CE, von Lindern M, van Hennik PB et al.. BIGH3 modulates adhesion and migration of hematopoietic stem and progenitor cells. Cell Adhes Migr. 2013; 7:434-449.
• [27]Gonsalves CS, Crable S, Chandra S, Li W, Kalra VK, Joiner CH. Angiogenic growth factors augment K-Cl cotransporter expression in erythroid cells via hypoxia-inducible factor-1alpha. Am J Hematol. 2014; 89:273-281.
• [28]Gordillo GM, Biswas A, Khanna S, Pan X, Sinha M, Roy S et al.. Dicer knockdown inhibits endothelial cell tumor growth via microRNA 21a-3p targeting of Nox-4. J Biol Chem. 2014; 289:9027-9038.
• [29]Serrano M, Moreno M, Ortega FJ, Xifra G, Ricart W, Moreno-Navarrete JM et al.. Adipose tissue mu-crystallin is a thyroid hormone-binding protein associated with systemic insulin sensitivity. J Clin Endocrinol Metab. 2014; 99:E2259-E2268.
• [30]Price FD, von Maltzahn J, Bentzinger CF, Dumont NA, Yin H, Chang NC et al.. Inhibition of JAK-STAT signaling stimulates adult satellite cell function. Nat Med. 2014; 20:1174-1181.
• [31]Bakhsheshian J, Hall MD, Robey RW, Herrmann MA, Chen JQ, Bates SE et al.. Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos. 2013; 41:1805-1812.
• [32]Choi YP, Lee JH, Gao MQ, Kim BG, Kang S, Kim SH et al.. Cancer-associated fibroblast promote transmigration through endothelial brain cells in three-dimensional in vitro models. Int J Cancer. 2014; 135:2024-2033.
• [33]Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, Volta M, Munsie LN, Chou P et al.. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci. 2014; 8:301.
• [34]Daniels VW, Smans K, Royaux I, Chypre M, Swinnen JV, Zaidi N. Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. PLoS One. 2014; 9:e106913.
• [35]Liu SB, Sardi S, Sonom B, Zocco D, McSweeney R, Fraser AD et al.. The application of a novel nanovolume capillary electrophoresis-based protein analysis system in personalized & translational medicine research. J Bioanal Biomed S. 2013; 3:004.
• [36]Kohn EA, Yang YA, Du Z, Nagano Y, Van Schyndle CM, Herrmann MA et al.. Biological responses to TGF-beta in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression. Mol Cancer Res. 2012; 10:1389-1399.
• [37]Sabnis H, Bradley HL, Bunting ST, Cooper TM, Bunting KD. Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia. J Transl Med. 2014; 12:166. BioMed Central Full Text
• [38]Kedei N, Lewin NE, Geczy T, Selezneva J, Braun DC, Chen J et al.. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1. ACS Chem Biol. 2013; 8:767-777.
• [39]DeChristopher BA, Fan AC, Felsher DW, Wender PA. “Picolog,” a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget. 2012; 3:58-66.
• [40]de Kreuk BJ, Anthony EC, Geerts D, Hordijk PL. The F-BAR protein PACSIN2 regulates epidermal growth factor receptor internalization. J Biol Chem. 2012; 287:43438-43453.
• [41]Fiscus RR, Leung EL, Wong JC, Johlfs MG (2012) Nitric oxide/protein kinase GIα promotes c-Src activation, proliferation and chemoresistance in ovarian cancer. In Farghaly DS (ed) Ovarian Cancer—Basic Science Perspective. InTech, pp 315–334
• [42]Aspinall-O’Dea M, Pierce A, Pellicano F, Williamson AJ, Scott MT, Walker MJ et al.. Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. Nat Protoc. 2015; 10:149-168.
• [43]Eldridge S, Guo L, Mussio J, Furniss M, Hamre J, Davis M. Examining the protective role of ErbB2 modulation in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2014; 141:547-559.
• [44]Frogne T, Sylvestersen KB, Kubicek S, Nielsen ML, Hecksher-Sorensen J. Pdx1 is post-translationally modified in vivo and serine 61 is the principal site of phosphorylation. PLoS One. 2012; 7:e35233.
• [45]Huang CC, Weng JH, Wei TY, Wu PY, Hsu PH, Chen YH et al.. Intermolecular binding between TIFA-FHA and TIFA-pT mediates tumor necrosis factor alpha stimulation and NF-kappaB activation. Mol Cell Biol. 2012; 32:2664-2673.
• [46]Sun Z, Li X, Massena S, Kutschera S, Padhan N, Gualandi L et al.. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. J Exp Med. 2012; 209:1363-1377.
• [47]Guo H, Gao M, Lu Y, Liang J, Lorenzi PL, Bai S et al.. Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene. 2014; 33:3463-3472.
• [48]Chen JQ, Lee JH, Herrmann MA, Park KS, Heldman MR, Goldsmith PK et al.. Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. Mol Cancer Ther. 2013; 12:2601-2613.
• [49]Icardi L, Mori R, Gesellchen V, Eyckerman S, De Cauwer L, Verhelst J et al.. The Sin3a repressor complex is a master regulator of STAT transcriptional activity. Proc Natl Acad Sci USA. 2012; 109:12058-12063.
• [50]Tikhanovich I, Kuravi S, Campbell RV, Kharbanda KK, Artigues A, Villar MT et al.. Regulation of FOXO3 by phosphorylation and methylation in hepatitis C virus infection and alcohol exposure. Hepatology. 2014; 59:58-70.
• [51]Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW et al.. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012; 36:98-103.
• [52]Fan AC, O’Rourke JJ, Praharaj DR, Felsher DW. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opin Investig Drugs. 2013; 22:1495-1509.
• [53]Hubbard MA, Khalil AA, Schoeff SS, Allak A, VanKoevering KK, Maxwell AK et al.. Nanoimmunoassay to detect responses in head and neck cancer: feasibility in a mouse model. Otolaryngol Head Neck Surg. 2014; 151:92-99.
• [54]Siggers P, Carre GA, Bogani D, Warr N, Wells S, Hilton H et al.. A novel mouse Fgfr2 mutant, hobbyhorse (hob), exhibits complete XY gonadal sex reversal. PLoS One. 2014; 9:e100447.
• [55]Drew DA, Devers T, Horelik N, Yang S, O’Brien M, Wu R et al.. Nanoproteomic analysis of extracellular receptor kinase-1/2 post-translational activation in microdissected human hyperplastic colon lesions. Proteomics. 2013; 13:1428-1436.
• [56]Goff DJ, Recart AC, Sadarangani A, Chun HJ, Barrett CL, Krajewska M et al.. A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013; 12:316-328.
• [57]Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ et al.. Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut. 2013; 62:1777-1786.
• [58]Williamson AJ, Pierce A, Jaworska E, Zhou C, Aspinall-O’Dea M, Lancashire L et al.. A specific PTPRC/CD45 phosphorylation event governed by stem cell chemokine CXCL12 regulates primitive hematopoietic cell motility. Mol Cell Proteomics. 2013; 12:3319-3329.
• [59]Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB et al.. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011; 118:6860-6870.
• [60]Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E et al.. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012; 18:1118-1122.
• [61]Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N et al.. BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood. 2013; 122:2864-2876.
• [62]Michels DA, Tu AW, McElroy W, Voehringer D, Salas-Solano O. Charge heterogeneity of monoclonal antibodies by multiplexed imaged capillary isoelectric focusing immunoassay with chemiluminescence detection. Anal Chem. 2012; 84:5380-5386.
• [63]Rustandi RR, Loughney JW, Hamm M, Hamm C, Lancaster C, Mach A et al.. Qualitative and quantitative evaluation of Simon, a new CE-based automated Western blot system as applied to vaccine development. Electrophoresis. 2012; 33:2790-2797.
• [64]Loughney JW, Lancaster C, Ha S, Rustandi RR. Residual bovine serum albumin (BSA) quantitation in vaccines using automated capillary western technology. Anal Biochem. 2014; 461:49-56.
• [65]Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L et al.. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010; 28:595-599.
• [66]Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci. 2008; 63:879-884.
• [67]Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000; 243:243-255.
• [68]Hoheisel JD, Alhamdani MS, Schroder C. Affinity-based microarrays for proteomic analysis of cancer tissues. Proteomics Clin Appl. 2013; 7:8-15.
• [69]Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24:971-983.
• [70]Kyselova Z, Mechref Y, Al Bataineh MM, Dobrolecki LE, Hickey RJ, Vinson J et al.. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res. 2007; 6:1822-1832.
• [71]Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC et al.. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011; 331:435-439.
• [72]Mueller C, Liotta LA, Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol. 2010; 4:461-481.
• [73]Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X et al.. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007; 67:3431-3440.
• [74]Zhu H, Cox E, Qian J. Functional protein microarray as molecular decathlete: a versatile player in clinical proteomics. Proteomics Clin Appl. 2012; 6:548-562.
• [75]Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J et al.. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer. 2007; 111:173-184.
• [76]Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M et al.. Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin Colorectal Cancer. 2009; 8:110-117.
• [77]Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D et al.. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003; 3:317-325.
• [78]Ellington AA, Kullo IJ, Bailey KR, Klee GG. Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem. 2010; 56:186-193.
• [79]Weibrecht I, Leuchowius KJ, Clausson CM, Conze T, Jarvius M, Howell WM et al.. Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev Proteomics. 2010; 7:401-409.
• [80]Seidal T, Balaton AJ, Battifora H. Interpretation and quantification of immunostains. Am J Surg Pathol. 2001; 25:1204-1207.
• [81]Haussmann U, Jahn O, Linning P, Janssen C, Liepold T, Portelius E et al.. Analysis of amino-terminal variants of amyloid-beta peptides by capillary isoelectric focusing immunoassay. Anal Chem. 2013; 85:8142-8149.
• [82]Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC et al.. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation. Biochem J. 2013; 452:313-320.
• [83]Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M et al.. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer. 2014; 14:120. BioMed Central Full Text
• [84]Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochemistry. 2013; 52:3797-3806.
• [85]Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM et al.. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol. 2009; 27:633-641.